A multiple lines of experimental studies [17,20,21] on type 1 or type 2 diabetic animals show that glycemic control with SGLT2 inhibitors reduces the progression of diabetic nephropathy, one of the major microvascular complications attributable to diabetes. This evidence concerns the gene SLC5A2 and diabetic kidney disease.